Sander Slootweg
Directeur/Bestuurslid bij FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Profiel
Sander Slootweg is currently serving as a Non-Executive Director at NewAmsterdam Pharma Co. NV, Director at Xention Ltd., Director at Replimune Group, Inc., Director at NorthSea Therapeutics BV, Director at Oxyrane Belgium NV, and Director at Azafaros BV.
Previously, he held positions as a Director at Fovea Pharmaceuticals SA, Investment Director at ABN Amro Capital Life Sciences, Director at Argenta Ltd., Director at Pulmagen Therapeutics LLP, Director at uniQure NV, Director at Pieris Pharmaceuticals, Inc., Director at Impella Cardiosystems AG, Director at Alantos Pharmaceuticals, Inc., and Director at Forbion European Acquisition Corp.
He also served as a Director at NewAmsterdam Pharma Holding BV from 2020 to 2022.
Mr. Slootweg completed his undergraduate studies at Nyenrode Business Universiteit and Vrije Universiteit Amsterdam.
Actieve functies van Sander Slootweg
| Bedrijven | Functie | Begin |
|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Directeur/Bestuurslid | - |
| REPLIMUNE GROUP, INC. | Directeur/Bestuurslid | - |
| Oxyrane Belgium NV | Directeur/Bestuurslid | - |
Xention Ltd.
 Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | Directeur/Bestuurslid | - |
Azafaros BV
 Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | Directeur/Bestuurslid | - |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Sander Slootweg
| Bedrijven | Functie | Einde |
|---|---|---|
| FORN EUROPAR | Directeur/Bestuurslid | 01-11-2023 |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Directeur/Bestuurslid | 01-11-2022 |
Argenta Ltd.
 Argenta Ltd. BiotechnologyHealth Technology Argenta Ltd. operates as a pharmaceutical contract manufacturing company. It serves animal health research, veterinary, and GMP manufacting. The company was founded by Douglas Robert Cleverly in 2006 and is headquartered in Manurewa, New Zealand. | Directeur/Bestuurslid | 01-01-2010 |
| ░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Sander Slootweg
| Vrije Universiteit Amsterdam | Undergraduate Degree |
| Nyenrode Business Universiteit | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Health Technology |
| REPLIMUNE GROUP, INC. | Health Technology |
| UNIQURE N.V. | Health Technology |
| PIERIS PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 12 |
|---|---|
Fovea Pharmaceuticals SA
 Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Health Technology |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Health Technology |
Azafaros BV
Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | Health Technology |
Xention Ltd.
Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | Health Technology |
| Oxyrane Belgium NV | |
Pulmagen Therapeutics LLP
 Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Health Technology |
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Health Technology |
Argenta Ltd.
Argenta Ltd. BiotechnologyHealth Technology Argenta Ltd. operates as a pharmaceutical contract manufacturing company. It serves animal health research, veterinary, and GMP manufacting. The company was founded by Douglas Robert Cleverly in 2006 and is headquartered in Manurewa, New Zealand. | Health Technology |
| Alantos Pharmaceuticals, Inc. | |
Impella Cardiosystems AG
 Impella Cardiosystems AG Medical SpecialtiesHealth Technology Impella Cardiosystems AG develops, manufactures, and markets minimally invasive cardiovascular support systems. The company is based in Aachen, Germany. The German company was founded by Thorsten Sieß. | Health Technology |
| ABN Amro Capital Life Sciences | |
Forbion European Acquisition Corp.
 Forbion European Acquisition Corp. Financial ConglomeratesFinance Forbion European Acquisition Corp. is a blank check company. It engages in the business of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded by Hugo Alexander Slootweg in 2006 and is headquartered in Wilmington, DE. | Finance |
